Американские товарищи посчитали стоит ли ввести рутинную практику проверки людей на ГепВ, построили математические модели и т. д., и у них получилось, что да, стоит, и они рекомендуют пересмотреть политику скрининга населения.
"While the most cost-effective treatment strategy for those found to be infected with HBV may evolve in the future, given newer and more effective agents or more complex therapies for patients who develop resistance, screening for chronic HBV infection is likely to be cost-effective, even in low-prevalence populations," he says. "These findings suggest that current health policy with regard to screening should be reconsidered, which could detect this life-threatening illness earlier, potentially saving more lives."
